Overview

A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis

Status:
Completed
Trial end date:
2018-02-07
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Hakko Kirin Co., Ltd
Kyowa Kirin Co., Ltd.
Treatments:
KHK4083